Miami Cancer Institute – Lung Cancer

Miami Cancer Institute – Lung Cancer is organized by Baptist Health South Florida.,,Course opens: 02/01/2022,Course expires: 12/31/2023,,Overview:,The state of knowledge regarding multimodality treatment for lung cancer is continually changing and it is important for surgeons, medical oncologists, radiation oncologists and pulmonologist to stay up to date on the latest recommendations for the management of the disease. Dr. Mark Dylewski and the distinguished faculty from Miami Cancer Institute and Lynn Cancer Institute will discuss new advances in the management of lung cancer.,,Learning Objectives:,• Develop selective strategies for determining the appropriate extent of resection for individual patients. ,• Assess the outcomes of patients experiencing complications after robotic pulmonary resection. ,• Identify treatment-related factors associated with an increased risk of major complications. ,• Identify the benefits of robotic intervention versus thoracotomy or conventional VATS techniques. ,• Describe the morbidity and mortality rates of complete resection associated with robotic surgery in the treatment of lung cancer. ,• Identify the principles of stereotactic body radiotherapy for early-stage non-small cell lung cancer.,• Analyze and assess outcomes for nonoperative management of locally advanced non-small cell lung cancer.,• Accurately assess and execute a thorough workup of a solitary lung nodule.,• Differentiate and evaluate treatment approaches of a lung nodule versus sampled nodule and when to proceed with surgical resection. ,• Evaluate bronchoscopic techniques, radial endobronchial ultrasound, navigation bronchoscopy, electromagnetic navigation and robotic platforms.,• Describe results of recent clinical trials that combine targeted therapies with chemotherapy.,• Implement strategies that optimize therapeutic decisions for patients based on individual molecular, genomic and clinical features.,• Analyze current strategies and standard of care for proper pretreatment of molecular and PDL-1 testing. ,• Execute appropriate treatment with immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer.,• Integrate gene mapping into professional practice updates when treating lung cancer.,• Identify the most effective treatment plan as a result of gene mapping. ,• Identify new treatments for resectable lung cancer.